Silicosis: Difference between revisions

(Moved intro into Background as bullets; removed excessive bold from bullet lead-ins; added Pulmonary fibrosis differential template; bold retained for critical items only)
(Strip excess bold)
 
Line 4: Line 4:
* High-risk occupations: Mining, quarrying, tunneling, sandblasting, construction (cutting/drilling concrete, brick, stone), foundry work, glass manufacturing, ceramics/pottery, gemstone cutting, dental laboratory work, stone countertop fabrication<ref name="StatPearls"/>
* High-risk occupations: Mining, quarrying, tunneling, sandblasting, construction (cutting/drilling concrete, brick, stone), foundry work, glass manufacturing, ceramics/pottery, gemstone cutting, dental laboratory work, stone countertop fabrication<ref name="StatPearls"/>
* The engineered stone epidemic:
* The engineered stone epidemic:
**Engineered stone ("quartz") countertops contain '''>90% crystalline silica''' (vs. granite ~30–50%, marble <10%)<ref name="AJRCCM2025"/>
**Engineered stone ("quartz") countertops contain >90% crystalline silica (vs. granite ~30–50%, marble <10%)<ref name="AJRCCM2025"/>
**US imports of engineered stone rose 800% from 2010 to 2018; now the most popular countertop material in the US<ref name="AJRCCM2025"/>
**US imports of engineered stone rose 800% from 2010 to 2018; now the most popular countertop material in the US<ref name="AJRCCM2025"/>
**By November 2024: 219 cases identified in California alone, including at least 14 deaths and 26 lung transplantations; median age 45; nearly all Latino immigrants<ref name="AJRCCM2025"/>
**By November 2024: 219 cases identified in California alone, including at least 14 deaths and 26 lung transplantations; median age 45; nearly all Latino immigrants<ref name="AJRCCM2025"/>
**Australia banned engineered stone effective July 2024 after 21% of screened workers were found to have silicosis<ref name="PMCReview">A review of silicosis and other silica-related diseases in the engineered stone countertop processing industry. ''J Occup Med Toxicol''. 2025.</ref>
**Australia banned engineered stone effective July 2024 after 21% of screened workers were found to have silicosis<ref name="PMCReview">A review of silicosis and other silica-related diseases in the engineered stone countertop processing industry. ''J Occup Med Toxicol''. 2025.</ref>
**Many workers present with '''accelerated''' disease — severe fibrosis after only 5–15 years of exposure, far more aggressive than traditional chronic silicosis<ref name="JAMA2023">Fazio J, et al. Silicosis among immigrant engineered stone countertop fabrication workers in California. ''JAMA Intern Med''. 2023.</ref>
**Many workers present with accelerated disease — severe fibrosis after only 5–15 years of exposure, far more aggressive than traditional chronic silicosis<ref name="JAMA2023">Fazio J, et al. Silicosis among immigrant engineered stone countertop fabrication workers in California. ''JAMA Intern Med''. 2023.</ref>
* Pathogenesis: Inhaled silica particles reach the terminal bronchioles and alveoli → engulfed by alveolar macrophages → macrophages cannot clear the particles → macrophage death releases silica and inflammatory mediators → cycle of chronic inflammation → fibroblast activation → '''irreversible nodular fibrosis'''<ref name="StatPearls"/>
* Pathogenesis: Inhaled silica particles reach the terminal bronchioles and alveoli → engulfed by alveolar macrophages → macrophages cannot clear the particles → macrophage death releases silica and inflammatory mediators → cycle of chronic inflammation → fibroblast activation → '''irreversible nodular fibrosis'''<ref name="StatPearls"/>
* Three forms of silicosis:
* Three forms of silicosis:
** Chronic (classic) silicosis: Most common; latency '''10–30+ years''' after moderate exposure; may be simple (small nodules) or complicated (progressive massive fibrosis/PMF)
** Chronic (classic) silicosis: Most common; latency 10–30+ years after moderate exposure; may be simple (small nodules) or complicated (progressive massive fibrosis/PMF)
** Accelerated silicosis: Higher exposure; latency '''5–10 years'''; clinically and pathologically similar to chronic silicosis but progresses faster; this is the predominant form in engineered stone workers<ref name="JAMA2023"/>
** Accelerated silicosis: Higher exposure; latency 5–10 years; clinically and pathologically similar to chronic silicosis but progresses faster; this is the predominant form in engineered stone workers<ref name="JAMA2023"/>
** Acute silicosis (silicoproteinosis): Intense exposure over '''weeks to months'''; clinically resembles [[pulmonary alveolar proteinosis]]; rapidly progressive; often fatal<ref name="Merck"/>
** Acute silicosis (silicoproteinosis): Intense exposure over '''weeks to months'''; clinically resembles [[pulmonary alveolar proteinosis]]; rapidly progressive; often fatal<ref name="Merck"/>
* Associated conditions:
* Associated conditions:
** [[Tuberculosis]]: Patients with silicosis have a '''~30-fold increased risk''' of TB (silicotuberculosis); even silica-exposed workers without silicosis have 3× the risk<ref name="Iowa">Silicosis. Iowa Health and Human Services. Updated August 2023.</ref>
** [[Tuberculosis]]: Patients with silicosis have a ~30-fold increased risk of TB (silicotuberculosis); even silica-exposed workers without silicosis have 3× the risk<ref name="Iowa">Silicosis. Iowa Health and Human Services. Updated August 2023.</ref>
** Lung cancer: Crystalline silica is IARC Group 1 carcinogen<ref name="Merck"/>
** Lung cancer: Crystalline silica is IARC Group 1 carcinogen<ref name="Merck"/>
** Autoimmune diseases: Increased risk of [[rheumatoid arthritis]] (Caplan syndrome — silicosis + rheumatoid nodules), [[scleroderma]], [[SLE]], [[ANCA-associated vasculitis]]<ref name="StatPearls"/>
** Autoimmune diseases: Increased risk of [[rheumatoid arthritis]] (Caplan syndrome — silicosis + rheumatoid nodules), [[scleroderma]], [[SLE]], [[ANCA-associated vasculitis]]<ref name="StatPearls"/>
Line 24: Line 24:


==Clinical Features==
==Clinical Features==
'''Chronic silicosis:'''
Chronic silicosis:
*Often '''asymptomatic''' for years — symptoms lag behind radiographic disease
*Often asymptomatic for years — symptoms lag behind radiographic disease
*Progressive '''exertional dyspnea''' (most common symptom)
*Progressive exertional dyspnea (most common symptom)
*Chronic dry cough (may become productive with superimposed infection)
*Chronic dry cough (may become productive with superimposed infection)
*Fatigue, reduced exercise tolerance
*Fatigue, reduced exercise tolerance
Line 32: Line 32:
* Progressive massive fibrosis (PMF): Coalescence of nodules into large opacities (>1 cm); marked dyspnea, severe restriction, respiratory failure<ref name="StatPearls"/>
* Progressive massive fibrosis (PMF): Coalescence of nodules into large opacities (>1 cm); marked dyspnea, severe restriction, respiratory failure<ref name="StatPearls"/>


'''Accelerated silicosis (engineered stone):'''
Accelerated silicosis (engineered stone):
*Younger patients (median ~45 years in US cases; some as young as late 20s)<ref name="JAMA2023"/>
*Younger patients (median ~45 years in US cases; some as young as late 20s)<ref name="JAMA2023"/>
*More rapid progression to PMF and respiratory failure
*More rapid progression to PMF and respiratory failure
*Many present with '''advanced disease at diagnosis''' — nearly half in the California cohort<ref name="JAMA2023"/>
*Many present with advanced disease at diagnosis — nearly half in the California cohort<ref name="JAMA2023"/>


'''Acute silicosis (silicoproteinosis):'''
Acute silicosis (silicoproteinosis):
*Onset weeks to few years after intense exposure
*Onset weeks to few years after intense exposure
*Rapidly progressive dyspnea, cough, weight loss, fatigue
*Rapidly progressive dyspnea, cough, weight loss, fatigue
*May present with '''acute respiratory failure'''
*May present with acute respiratory failure
*Resembles [[pulmonary alveolar proteinosis]] clinically and radiographically (bilateral alveolar filling pattern)<ref name="Merck"/>
*Resembles [[pulmonary alveolar proteinosis]] clinically and radiographically (bilateral alveolar filling pattern)<ref name="Merck"/>
*Poor prognosis; often fatal<ref name="Merck"/>
*Poor prognosis; often fatal<ref name="Merck"/>


'''ED presentations:'''
ED presentations:
*Progressive dyspnea with occupational exposure history
*Progressive dyspnea with occupational exposure history
*Superimposed respiratory infection ('''always consider TB''' — silicotuberculosis)
*Superimposed respiratory infection (always consider TB — silicotuberculosis)
*Spontaneous [[pneumothorax]]
*Spontaneous [[pneumothorax]]
*Acute respiratory failure (acute silicosis or end-stage chronic disease)
*Acute respiratory failure (acute silicosis or end-stage chronic disease)
Line 69: Line 69:
==Evaluation==
==Evaluation==
===Workup===
===Workup===
'''History — critical:'''
History — critical:
* Detailed occupational history: All current and prior jobs; specifically ask about mining, construction, sandblasting, foundry, ceramics, glass, stone cutting/fabrication/installation, demolition, tunneling, dental lab work
* Detailed occupational history: All current and prior jobs; specifically ask about mining, construction, sandblasting, foundry, ceramics, glass, stone cutting/fabrication/installation, demolition, tunneling, dental lab work
* Ask specifically about stone countertop work — engineered stone/quartz/artificial stone fabrication, cutting, polishing, installation; many workers may not realize this is a silica-exposure occupation<ref name="AJRCCM2025"/>
* Ask specifically about stone countertop work — engineered stone/quartz/artificial stone fabrication, cutting, polishing, installation; many workers may not realize this is a silica-exposure occupation<ref name="AJRCCM2025"/>
Line 77: Line 77:
*Immigration status may affect healthcare access — provide resources regardless of documentation status
*Immigration status may affect healthcare access — provide resources regardless of documentation status


'''Laboratory (ED):'''
Laboratory (ED):
*CBC, CMP
*CBC, CMP
*ABG/VBG: Hypoxemia; exercise desaturation in moderate disease
*ABG/VBG: Hypoxemia; exercise desaturation in moderate disease
Line 86: Line 86:
*BNP/NT-proBNP if [[cor pulmonale]] or right heart failure suspected
*BNP/NT-proBNP if [[cor pulmonale]] or right heart failure suspected


'''Imaging:'''
Imaging:


''Chest X-ray:''
''Chest X-ray:''
Line 97: Line 97:


''HRCT — more sensitive than CXR:''
''HRCT — more sensitive than CXR:''
*Small centrilobular and subpleural nodules, '''upper-zone predominant'''
*Small centrilobular and subpleural nodules, upper-zone predominant
*Nodule coalescence in PMF
*Nodule coalescence in PMF
*Associated emphysema
*Associated emphysema
Line 104: Line 104:
*HRCT can detect silicosis when CXR is normal — CXR sensitivity for silicosis is only 35–48% compared to HRCT<ref name="PMCReview"/>
*HRCT can detect silicosis when CXR is normal — CXR sensitivity for silicosis is only 35–48% compared to HRCT<ref name="PMCReview"/>


'''PFTs''' (outpatient):
PFTs (outpatient):
*May be '''normal''' in simple chronic silicosis
*May be normal in simple chronic silicosis
* Restrictive pattern most common (reduced FVC, TLC)
* Restrictive pattern most common (reduced FVC, TLC)
* Obstructive pattern may be seen (especially with concurrent COPD/emphysema)
* Obstructive pattern may be seen (especially with concurrent COPD/emphysema)
Line 122: Line 122:


==Management==
==Management==
'''There is no cure for silicosis — management is entirely supportive and preventive'''<ref name="Merck"/>
There is no cure for silicosis — management is entirely supportive and preventive<ref name="Merck"/>


'''1. Remove from further silica exposure''' — the most important intervention; though disease may progress even after exposure ceases<ref name="ATS2014">Balmes JR, et al. ATS Statement. ''Am J Respir Crit Care Med''. 2014.</ref>
'''1. Remove from further silica exposure''' — the most important intervention; though disease may progress even after exposure ceases<ref name="ATS2014">Balmes JR, et al. ATS Statement. ''Am J Respir Crit Care Med''. 2014.</ref>


'''2. ED management:'''
2. ED management:
*Supplemental O2 to maintain SpO2 ≥90%
*Supplemental O2 to maintain SpO2 ≥90%
*Bronchodilators (albuterol, ipratropium) — may benefit patients with obstructive component; ~25% have bronchodilator responsiveness<ref name="Merck"/>
*Bronchodilators (albuterol, ipratropium) — may benefit patients with obstructive component; ~25% have bronchodilator responsiveness<ref name="Merck"/>
Line 135: Line 135:
*Treat cor pulmonale/right heart failure if present (diuretics, supplemental O2)
*Treat cor pulmonale/right heart failure if present (diuretics, supplemental O2)


'''3. TB management in silicosis:'''
3. TB management in silicosis:
* Latent TB infection: Treatment is strongly recommended in all silicosis patients with positive TST or IGRA, regardless of age<ref name="Merck"/>
* Latent TB infection: Treatment is strongly recommended in all silicosis patients with positive TST or IGRA, regardless of age<ref name="Merck"/>
* Active TB: Standard anti-TB regimens; may require prolonged treatment courses due to higher treatment failure rates in silicotuberculosis<ref name="Iowa"/>
* Active TB: Standard anti-TB regimens; may require prolonged treatment courses due to higher treatment failure rates in silicotuberculosis<ref name="Iowa"/>
*Screen annually with TST or IGRA<ref name="Merck"/>
*Screen annually with TST or IGRA<ref name="Merck"/>


'''4. Acute silicosis (silicoproteinosis):'''
4. Acute silicosis (silicoproteinosis):
* Whole lung lavage has been used (similar to treatment for pulmonary alveolar proteinosis); clinical benefit not well established<ref name="Merck"/>
* Whole lung lavage has been used (similar to treatment for pulmonary alveolar proteinosis); clinical benefit not well established<ref name="Merck"/>
*Systemic corticosteroids — limited evidence; may provide modest benefit
*Systemic corticosteroids — limited evidence; may provide modest benefit
*Prognosis is poor regardless of treatment
*Prognosis is poor regardless of treatment


'''5. Long-term management (coordinate with pulmonology/occupational medicine):'''
5. Long-term management (coordinate with pulmonology/occupational medicine):
*Smoking cessation (mandatory — compounds injury and cancer risk)
*Smoking cessation (mandatory — compounds injury and cancer risk)
*Pulmonary rehabilitation
*Pulmonary rehabilitation
Line 154: Line 154:
*No proven antifibrotic therapy for silicosis (nintedanib and pirfenidone have not been specifically studied in silicosis)
*No proven antifibrotic therapy for silicosis (nintedanib and pirfenidone have not been specifically studied in silicosis)


'''6. Reporting:'''
6. Reporting:
*Silicosis is a '''reportable occupational disease''' in most jurisdictions — notify public health/occupational health authorities
*Silicosis is a reportable occupational disease in most jurisdictions — notify public health/occupational health authorities
*Document occupational exposure history thoroughly (may be needed for workers' compensation claims)
*Document occupational exposure history thoroughly (may be needed for workers' compensation claims)


Latest revision as of 09:29, 22 March 2026

Background

  • Silicosis is an irreversible occupational lung disease caused by inhalation of respirable crystalline silica (silicon dioxide) dust, resulting in progressive nodular pulmonary fibrosis.[1] It is the world's most prevalent occupational lung disease and has no cure.[1] Once considered a disease of the past in developed countries, silicosis is experiencing a resurgence driven by engineered stone (quartz) countertop fabrication, which has created a new epidemic predominantly affecting young immigrant workers.[2] Silica is classified as a Group 1 human lung carcinogen by IARC.[3] The ED physician will encounter silicosis patients presenting with progressive dyspnea, respiratory infections (especially tuberculosis), pneumothorax, and acute respiratory failure.
  • Crystalline silica (quartz) is one of the most abundant minerals on earth; occupational exposure occurs when silica-containing materials are cut, ground, drilled, or blasted, generating respirable dust (<10 µm)[1]
  • High-risk occupations: Mining, quarrying, tunneling, sandblasting, construction (cutting/drilling concrete, brick, stone), foundry work, glass manufacturing, ceramics/pottery, gemstone cutting, dental laboratory work, stone countertop fabrication[1]
  • The engineered stone epidemic:
    • Engineered stone ("quartz") countertops contain >90% crystalline silica (vs. granite ~30–50%, marble <10%)[2]
    • US imports of engineered stone rose 800% from 2010 to 2018; now the most popular countertop material in the US[2]
    • By November 2024: 219 cases identified in California alone, including at least 14 deaths and 26 lung transplantations; median age 45; nearly all Latino immigrants[2]
    • Australia banned engineered stone effective July 2024 after 21% of screened workers were found to have silicosis[4]
    • Many workers present with accelerated disease — severe fibrosis after only 5–15 years of exposure, far more aggressive than traditional chronic silicosis[5]
  • Pathogenesis: Inhaled silica particles reach the terminal bronchioles and alveoli → engulfed by alveolar macrophages → macrophages cannot clear the particles → macrophage death releases silica and inflammatory mediators → cycle of chronic inflammation → fibroblast activation → irreversible nodular fibrosis[1]
  • Three forms of silicosis:
    • Chronic (classic) silicosis: Most common; latency 10–30+ years after moderate exposure; may be simple (small nodules) or complicated (progressive massive fibrosis/PMF)
    • Accelerated silicosis: Higher exposure; latency 5–10 years; clinically and pathologically similar to chronic silicosis but progresses faster; this is the predominant form in engineered stone workers[5]
    • Acute silicosis (silicoproteinosis): Intense exposure over weeks to months; clinically resembles pulmonary alveolar proteinosis; rapidly progressive; often fatal[3]
  • Associated conditions:
  • OSHA PEL: 50 µg/m³ (8-hour TWA); updated in 2016[3]

Clinical Features

Chronic silicosis:

  • Often asymptomatic for years — symptoms lag behind radiographic disease
  • Progressive exertional dyspnea (most common symptom)
  • Chronic dry cough (may become productive with superimposed infection)
  • Fatigue, reduced exercise tolerance
  • Physical exam: May be normal early; bibasal inspiratory crackles; advanced disease: signs of right heart failure (cor pulmonale), clubbing (uncommon unless complicated by other ILD or malignancy)
  • Progressive massive fibrosis (PMF): Coalescence of nodules into large opacities (>1 cm); marked dyspnea, severe restriction, respiratory failure[1]

Accelerated silicosis (engineered stone):

  • Younger patients (median ~45 years in US cases; some as young as late 20s)[5]
  • More rapid progression to PMF and respiratory failure
  • Many present with advanced disease at diagnosis — nearly half in the California cohort[5]

Acute silicosis (silicoproteinosis):

  • Onset weeks to few years after intense exposure
  • Rapidly progressive dyspnea, cough, weight loss, fatigue
  • May present with acute respiratory failure
  • Resembles pulmonary alveolar proteinosis clinically and radiographically (bilateral alveolar filling pattern)[3]
  • Poor prognosis; often fatal[3]

ED presentations:

  • Progressive dyspnea with occupational exposure history
  • Superimposed respiratory infection (always consider TB — silicotuberculosis)
  • Spontaneous pneumothorax
  • Acute respiratory failure (acute silicosis or end-stage chronic disease)
  • Hemoptysis (from PMF cavitation, TB, or broncholithiasis)
  • Incidental finding of bilateral upper-lobe nodules on CT obtained for another reason

Differential Diagnosis

  • Tuberculosis (may coexist with silicosis — silicotuberculosis; cavitary lesions in PMF raise concern for TB superinfection)
  • Sarcoidosis (bilateral hilar lymphadenopathy + upper-lobe nodules; noncaseating granulomas; no occupational exposure)
  • Chronic beryllium disease (requires BeLPT to distinguish; identical imaging possible)
  • Other pneumoconioses: Asbestosis (basal-predominant fibrosis + pleural plaques), coal workers' pneumoconiosis (similar imaging but different exposure)
  • Idiopathic pulmonary fibrosis (basal-predominant; UIP pattern; no occupational exposure)
  • Hypersensitivity pneumonitis (exposure history differs; centrilobular nodules and air trapping)
  • Pulmonary alveolar proteinosis (for acute silicosis — "crazy-paving" pattern)
  • Metastatic disease or lymphoma (for PMF masses)
  • Lung cancer (may coexist; silica is carcinogenic)
  • Fungal infections (histoplasmosis, coccidioidomycosis)


Pulmonary Fibrosis

Evaluation

Workup

History — critical:

  • Detailed occupational history: All current and prior jobs; specifically ask about mining, construction, sandblasting, foundry, ceramics, glass, stone cutting/fabrication/installation, demolition, tunneling, dental lab work
  • Ask specifically about stone countertop work — engineered stone/quartz/artificial stone fabrication, cutting, polishing, installation; many workers may not realize this is a silica-exposure occupation[2]
  • Duration of exposure, use of respiratory protection, wet vs. dry cutting methods
  • Smoking history (compounds risk; assess for concomitant COPD)
  • TB risk factors and prior testing
  • Immigration status may affect healthcare access — provide resources regardless of documentation status

Laboratory (ED):

  • CBC, CMP
  • ABG/VBG: Hypoxemia; exercise desaturation in moderate disease
  • Sputum for AFB smear, culture, and mycobacterial PCR if TB suspected (silicotuberculosis)
  • Annual TB screening is recommended for all silica-exposed patients (tuberculin skin test or IGRA) — initiate if not recently done[3]
  • No specific serum biomarker for silicosis
  • Procalcitonin, blood cultures if concurrent infection suspected
  • BNP/NT-proBNP if cor pulmonale or right heart failure suspected

Imaging:

Chest X-ray:

  • Small round opacities in the upper and middle lung zones — the classic finding; graded by ILO classification (profusion and size: p, q, r)[1]
  • Eggshell calcification of hilar lymph nodes — not pathognomonic but highly suggestive (~5–10% of cases)[7]
  • Progressive massive fibrosis (PMF): Large opacities (>1 cm), typically in upper lobes, often bilateral and symmetric; may cavitate (raises concern for TB, anaerobic infection, or necrosis)
  • Hilar and mediastinal lymphadenopathy
  • Compensatory emphysema peripheral to conglomerate nodules
  • Acute silicosis: Bilateral alveolar/ground-glass pattern resembling pulmonary edema or alveolar proteinosis; Kerley B lines; pleural effusions may occur[8]

HRCT — more sensitive than CXR:

  • Small centrilobular and subpleural nodules, upper-zone predominant
  • Nodule coalescence in PMF
  • Associated emphysema
  • Ground-glass opacities (acute or accelerated forms)
  • Mediastinal/hilar lymphadenopathy (may show eggshell calcification)
  • HRCT can detect silicosis when CXR is normal — CXR sensitivity for silicosis is only 35–48% compared to HRCT[4]

PFTs (outpatient):

  • May be normal in simple chronic silicosis
  • Restrictive pattern most common (reduced FVC, TLC)
  • Obstructive pattern may be seen (especially with concurrent COPD/emphysema)
  • Mixed restrictive-obstructive pattern in advanced disease
  • Reduced DLCO[1]

Diagnosis

  • Three elements:[7]
    • (1) History of sufficient occupational silica exposure
    • (2) Chest imaging consistent with silicosis (CXR or HRCT)
    • (3) Exclusion of other conditions that better explain the findings
  • Tissue biopsy is generally NOT required — clinical-radiographic diagnosis is sufficient in most cases[1]
  • Biopsy (transbronchial or surgical) if diagnosis is uncertain: concentric whorled collagenous nodules (silicotic nodules) with birefringent particles under polarized light[1]
  • Always exclude TB — sputum AFB, cultures, +/- PCR in any patient with silicosis and new symptoms, cavitary lesions, or fever
  • In the ED: Consider silicosis in any patient with bilateral upper-lobe nodularity or fibrosis + occupational exposure history; ensure appropriate referral even if the patient presents for an unrelated complaint

Management

There is no cure for silicosis — management is entirely supportive and preventive[3]

1. Remove from further silica exposure — the most important intervention; though disease may progress even after exposure ceases[9]

2. ED management:

  • Supplemental O2 to maintain SpO2 ≥90%
  • Bronchodilators (albuterol, ipratropium) — may benefit patients with obstructive component; ~25% have bronchodilator responsiveness[3]
  • Non-invasive ventilation or intubation for respiratory failure
  • Treat superimposed infection aggressively
  • If TB suspected: Respiratory isolation, sputum AFB ×3, initiate empiric TB therapy if high clinical suspicion (silicotuberculosis has higher treatment failure and mortality than TB alone)[3]
  • Chest tube for pneumothorax
  • Treat cor pulmonale/right heart failure if present (diuretics, supplemental O2)

3. TB management in silicosis:

  • Latent TB infection: Treatment is strongly recommended in all silicosis patients with positive TST or IGRA, regardless of age[3]
  • Active TB: Standard anti-TB regimens; may require prolonged treatment courses due to higher treatment failure rates in silicotuberculosis[6]
  • Screen annually with TST or IGRA[3]

4. Acute silicosis (silicoproteinosis):

  • Whole lung lavage has been used (similar to treatment for pulmonary alveolar proteinosis); clinical benefit not well established[3]
  • Systemic corticosteroids — limited evidence; may provide modest benefit
  • Prognosis is poor regardless of treatment

5. Long-term management (coordinate with pulmonology/occupational medicine):

  • Smoking cessation (mandatory — compounds injury and cancer risk)
  • Pulmonary rehabilitation
  • Supplemental O2 for chronic hypoxemia
  • Vaccinations: Annual influenza, pneumococcal, COVID-19
  • Lung cancer screening (silica is Group 1 carcinogen)[3]
  • Lung transplantation for end-stage disease (PMF with respiratory failure); increasing demand from engineered stone workers[2]
  • No proven antifibrotic therapy for silicosis (nintedanib and pirfenidone have not been specifically studied in silicosis)

6. Reporting:

  • Silicosis is a reportable occupational disease in most jurisdictions — notify public health/occupational health authorities
  • Document occupational exposure history thoroughly (may be needed for workers' compensation claims)

Disposition

  • Admit:
    • Acute respiratory failure
    • Suspected silicotuberculosis (respiratory isolation pending AFB results)
    • Acute silicosis with progressive hypoxemia
    • Pneumothorax requiring chest tube
    • Hemoptysis requiring evaluation (PMF cavitation, TB, malignancy)
    • Severe exacerbation of known silicosis (infection, cor pulmonale)
  • Discharge with close follow-up:
    • Stable known silicosis with mild respiratory symptoms at baseline
    • New suspected silicosis in stable patient — arrange:
      • Pulmonology and/or occupational medicine referral within 1–2 weeks
      • HRCT if not performed (CXR alone has low sensitivity)
      • PFTs with DLCO
      • TB screening (TST or IGRA) if not recently performed
    • Discharge counseling:
      • Avoid further silica exposure — discuss with employer; may require job change or engineering controls (wet cutting, ventilation, respirators)
      • Return for worsening dyspnea, fever, hemoptysis, chest pain
      • Smoking cessation
      • Ensure vaccinations are current
      • Report to occupational health for workplace evaluation and coworker screening
      • For engineered stone workers: The LAM Foundation and occupational health resources may provide guidance; connect with legal resources if appropriate as this is an area of active litigation and compensation

See Also

External Links

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 Silicosis. StatPearls. NCBI Bookshelf. Updated August 2023.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Heinzerling A, et al. Deadly countertops: an urgent need to eliminate silicosis among engineered stone workers. Am J Respir Crit Care Med. 2025.
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 Silicosis. Merck Manual Professional Edition. Updated April 2025.
  4. ↑ 4.0 4.1 A review of silicosis and other silica-related diseases in the engineered stone countertop processing industry. J Occup Med Toxicol. 2025.
  5. ↑ 5.0 5.1 5.2 5.3 Fazio J, et al. Silicosis among immigrant engineered stone countertop fabrication workers in California. JAMA Intern Med. 2023.
  6. ↑ 6.0 6.1 6.2 6.3 Silicosis. Iowa Health and Human Services. Updated August 2023.
  7. ↑ 7.0 7.1 Silicosis. Wikipedia. Updated March 2026.
  8. ↑ Managing silicosis in the United States. CHEST Pulmonary. 2024.
  9. ↑ Balmes JR, et al. ATS Statement. Am J Respir Crit Care Med. 2014.
Retrieved from "https://www.wikem.org/w/index.php?title=Silicosis&oldid=389181"